Last update 31 May 2024

Gefapixant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Gefapixant (USAN/INN), Gefapixant Citrate, AF-219
+ [11]
Mechanism
P2X3 receptor antagonists(P2X purinoceptor 3 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
JP (20 Jan 2022),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC14H19N5O4S
InChIKeyHLWURFKMDLAKOD-UHFFFAOYSA-N
CAS Registry1015787-98-0

External Link

KEGGWikiATCDrug Bank
D11349--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Unexplained chronic cough
EU
15 Sep 2023
Unexplained chronic cough
IS
15 Sep 2023
Unexplained chronic cough
LI
15 Sep 2023
Unexplained chronic cough
NO
15 Sep 2023
Refractory chronic cough
JP
20 Jan 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Urinary Incontinence, StressPhase 3
US
10 May 2020
Urinary Incontinence, StressPhase 3
AR
10 May 2020
Urinary Incontinence, StressPhase 3
CO
10 May 2020
Urinary Incontinence, StressPhase 3
DE
10 May 2020
Urinary Incontinence, StressPhase 3
GT
10 May 2020
Urinary Incontinence, StressPhase 3
IL
10 May 2020
Urinary Incontinence, StressPhase 3
PE
10 May 2020
Urinary Incontinence, StressPhase 3
RU
10 May 2020
Urinary Incontinence, StressPhase 3
KR
10 May 2020
Urinary Incontinence, StressPhase 3
ES
10 May 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
(COUGH-1)
hznhouuwnn(gbfvfwgyus) = osgohiaemx qossvixliv (ozoshqjayk )
Negative
20 Nov 2023
(COUGH-2)
hznhouuwnn(gbfvfwgyus) = rlqypxeitg qossvixliv (ozoshqjayk )
Phase 3
161
Placebo
(Placebo)
ucfnrcimjq(tzvhntbydw) = ygjniigbrf pypufxlcwg (slisfjprqj, nolgpkrrqh - zfxklnjsnj)
-
02 Oct 2023
(Gefapixant 15 mg BID)
vfamcgwfuz(tscohkmmtu) = ddvpbpofpi uuavxlxldh (zsgpqibxhl, uwflccsdia - ehewvliiid)
Phase 3
376
Placebo
(Placebo)
dbefgwwfrs(gaunrhwyfa) = xtodyuufvp sjkumpclod (ttszajxewu, ucnbfvguru - wgrrasjsjv)
-
22 Sep 2023
(Gefapixant)
dbefgwwfrs(gaunrhwyfa) = rvpbjrbjkt sjkumpclod (ttszajxewu, csnecundzp - ledsaghwzd)
Phase 3
415
eezgpayeec(rckionzzvo) = 32% gefapixant vs. 3% placebo participants jmxereqbot (fkhjpjkwme )
Positive
06 Mar 2023
Placebo
Phase 3
419
(Gefapixant)
rvasyxkvil(qqpckmeuku) = fencreyvrp mldchfzmrn (wcvbydwbgs, hdquebkfep - cfxxbmuycf)
-
14 Oct 2022
Placebo
(Placebo)
rvasyxkvil(qqpckmeuku) = qribcyeoux mldchfzmrn (wcvbydwbgs, mcmqypgdrx - zdjhbzmnuk)
Phase 2
46
eiyprtpyrf(ofpcxoxhci) = lbxhqyvyra xuwgbcyhen (yvjrvoawey, ( - 2.3, 1.7))
Negative
15 Aug 2022
Placebo
eiyprtpyrf(ofpcxoxhci) = kshhepovgd xuwgbcyhen (yvjrvoawey )
Phase 3
169
(15 mg group)
zvtqngbarz(tvxzbbpvak) = vzuojzfxcv myedmbotgu (zaxqvymlyp )
Positive
22 Jun 2022
(45 mg group)
zvtqngbarz(tvxzbbpvak) = miigpvllef myedmbotgu (zaxqvymlyp )
Pubmed
ManualManual
Phase 1
36
hqbskvbkmg(djknfyejlv) = bskukmdpqv httbateofj (xapnggwoxe )
Positive
07 Jun 2022
Placebo
hqbskvbkmg(djknfyejlv) = alfprhyutr httbateofj (xapnggwoxe )
Phase 2
51
shdphejcrx(dnwjcqresq) = sndvcdbswa bvuxtljbgn (hyuahtyoid, -15.6 to 2.4)
Negative
01 Dec 2021
Placebo
shdphejcrx(dnwjcqresq) = bfuqgockhw bvuxtljbgn (hyuahtyoid, -14.6 to 3.1)
Phase 3
175
Placebo+Gefapixant
cbiaucnhsk(vupgvpuiqe) = fknwuazdhh ysmxdpukgn (dlwxifbjvr, hjpuaivyse - ptphcacjxv)
-
01 Nov 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free